Comparative benchmarking of CRISPRi and CasRx in standardized pluripotent stem cell platforms reveals context-dependent knockdown performance

Avatar
Poster
Voice is AI-generated
Connected to paperThis paper is a preprint and has not been certified by peer review

Comparative benchmarking of CRISPRi and CasRx in standardized pluripotent stem cell platforms reveals context-dependent knockdown performance

Authors

Ni, L.; Murakami, T.; Suzuki, S.; Hamao, M.; Nakamura, M.; Okubo, C.; Takahashi, K.

Abstract

Advances in transcriptome profiling have revealed transcriptomic differences across different cellular states. However, functional interpretation requires precise perturbation tools and experimental frameworks. This study benchmarked two widely used modalities: CRISPR interference (CRISPRi) and Cas13d/CasRx. A standardized workflow was established to generate human pluripotent stem cells (PSCs) with inducible ZIM3-dCas9 or CasRx expression. The cell lines were subjected to flow cytometry, copy number, and immunocytochemical analyses. The knockdown performance was validated via robust OCT4 suppression and the expected downstream effects on pluripotency genes. Time-course measurements indicated that CRISPRi produced faster and stronger repression but slower recovery after inducer withdrawal. In contrast, CasRx yielded slower and typically weaker knockdown with rapid reversibility. Furthermore, a key limitation of CRISPRi was demonstrated using the ATF5-NUP62 locus, wherein CRISPRi could co-repress genes with overlapping promoter regions. In contrast, CasRx avoids these limitations and supports isoform-resolved targeting of circular and alternatively spliced transcripts, albeit with variable efficiency. These results provide practical guidance for selecting complementary knockdown tools to improve the interpretability of transcriptomic function studies.

Follow Us on

0 comments

Add comment